Relief Therapeutics Holding AG (RLFTF)
USD 4.9
(0.0%)
USD 4.9
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 76.39 Million CHF | -59.54% |
| 2022 | 188.79 Million CHF | -24.97% |
| 2021 | 251.61 Million CHF | 222.4% |
| 2020 | 78.04 Million CHF | 292.92% |
| 2019 | 19.86 Million CHF | -44.17% |
| 2018 | 35.57 Million CHF | 14.87% |
| 2017 | 30.97 Million CHF | -1.44% |
| 2016 | 31.42 Million CHF | 4.28% |
| 2015 | 30.13 Million CHF | -27.6% |
| 2014 | 41.62 Million CHF | -9.48% |
| 2013 | 45.98 Million CHF | 3471.27% |
| 2012 | 1.28 Million CHF | -60.71% |
| 2011 | 3.27 Million CHF | -94.38% |
| 2010 | 58.3 Million CHF | -10.6% |
| 2009 | 65.21 Million CHF | -14.93% |
| 2008 | 76.66 Million CHF | -3.12% |
| 2007 | 79.13 Million CHF | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 70.92 Million CHF | -7.16% |
| 2024 Q2 | 70.92 Million CHF | 0.0% |
| 2023 Q2 | 125.77 Million CHF | 0.0% |
| 2023 FY | 76.39 Million CHF | -59.54% |
| 2023 Q4 | 76.39 Million CHF | 0.0% |
| 2023 Q3 | 76.39 Million CHF | -39.27% |
| 2023 Q1 | 125.77 Million CHF | -33.38% |
| 2022 Q4 | 188.79 Million CHF | 0.0% |
| 2022 Q1 | 221.82 Million CHF | -11.84% |
| 2022 Q3 | 188.79 Million CHF | -14.89% |
| 2022 FY | 188.79 Million CHF | -24.97% |
| 2022 Q2 | 221.82 Million CHF | 0.0% |
| 2021 Q4 | 251.61 Million CHF | 0.0% |
| 2021 FY | 251.61 Million CHF | 222.4% |
| 2021 Q1 | 179.98 Million CHF | 130.61% |
| 2021 Q2 | 179.98 Million CHF | 0.0% |
| 2021 Q3 | 251.61 Million CHF | 39.8% |
| 2020 Q4 | 78.04 Million CHF | 0.0% |
| 2020 Q2 | 34.34 Million CHF | 0.0% |
| 2020 Q1 | 34.34 Million CHF | 72.9% |
| 2020 FY | 78.04 Million CHF | 292.92% |
| 2020 Q3 | 78.04 Million CHF | 127.24% |
| 2019 FY | 19.86 Million CHF | -44.17% |
| 2019 Q4 | 19.86 Million CHF | 0.0% |
| 2019 Q1 | 31.04 Million CHF | -12.75% |
| 2019 Q2 | 31.04 Million CHF | 0.0% |
| 2019 Q3 | 19.86 Million CHF | -36.01% |
| 2018 Q2 | 35.4 Million CHF | 0.0% |
| 2018 Q4 | 35.57 Million CHF | 0.0% |
| 2018 FY | 35.57 Million CHF | 14.87% |
| 2018 Q3 | 35.57 Million CHF | 0.48% |
| 2018 Q1 | 35.4 Million CHF | 14.32% |
| 2017 FY | 30.97 Million CHF | -1.44% |
| 2017 Q4 | 30.97 Million CHF | 0.0% |
| 2017 Q3 | 30.97 Million CHF | -0.71% |
| 2017 Q2 | 31.19 Million CHF | 0.0% |
| 2017 Q1 | 31.19 Million CHF | -0.73% |
| 2016 FY | 31.42 Million CHF | 4.28% |
| 2016 Q4 | 31.42 Million CHF | 0.0% |
| 2016 Q3 | 31.42 Million CHF | 37.36% |
| 2016 Q2 | 22.87 Million CHF | 0.0% |
| 2016 Q1 | - CHF | -100.0% |
| 2015 Q2 | 31.57 Million CHF | 0.0% |
| 2015 FY | 30.13 Million CHF | -27.6% |
| 2015 Q4 | 30.13 Million CHF | 0.0% |
| 2014 Q4 | 41.62 Million CHF | 0.0% |
| 2014 FY | 41.62 Million CHF | -9.48% |
| 2014 Q2 | 41.57 Million CHF | 0.0% |
| 2013 FY | 45.98 Million CHF | 3471.27% |
| 2013 Q2 | 1.09 Million CHF | 0.0% |
| 2013 Q4 | 45.98 Million CHF | 0.0% |
| 2012 Q4 | 1.28 Million CHF | 0.0% |
| 2012 FY | 1.28 Million CHF | -60.71% |
| 2012 Q2 | 1.33 Million CHF | 0.0% |
| 2011 FY | 3.27 Million CHF | -94.38% |
| 2011 Q2 | 11.97 Million CHF | 0.0% |
| 2011 Q4 | 3.27 Million CHF | 0.0% |
| 2010 Q2 | 61.85 Million CHF | 0.0% |
| 2010 FY | 58.3 Million CHF | -10.6% |
| 2010 Q4 | 58.3 Million CHF | 0.0% |
| 2009 Q4 | 65.21 Million CHF | 0.0% |
| 2009 Q2 | 76.8 Million CHF | 0.0% |
| 2009 FY | 65.21 Million CHF | -14.93% |
| 2008 FY | 76.66 Million CHF | -3.12% |
| 2008 Q4 | 76.66 Million CHF | 0.0% |
| 2007 FY | 79.13 Million CHF | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -96.643% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -958.068% |
| SQZ Biotechnologies Company | 107.18 Million USD | 28.732% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -623.801% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 41.334% |
| Mesoblast Limited | 667.9 Million USD | 88.563% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -105462.081% |
| Genus plc | 1.02 Billion USD | 92.576% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -5523.722% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -15207.421% |
| Marizyme, Inc. | 22.01 Million USD | -246.99% |
| ContraFect Corporation | 20.67 Million USD | -269.409% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -12083.413% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -19468.815% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -19888.121% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -5234.378% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -1742.489% |
| MultiCell Technologies, Inc. | 126.22 USD | -60521211.995% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -8029.285% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 40.557% |
| EV Biologics, Inc. | 431.71 Thousand USD | -17594.585% |
| Q BioMed Inc. | 3.51 Million USD | -2072.938% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -117.147% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -9812.489% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -29137.17% |
| Biomind Labs Inc. | 73.81 Thousand USD | -103382.843% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 83.496% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -154.506% |
| Skye Bioscience, Inc. | 11.94 Million USD | -539.76% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -2205.757% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -2681.525% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -3801.053% |
| IMV Inc. | 31.33 Million USD | -143.794% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -11011.499% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -2834.47% |
| GB Sciences, Inc. | 103.44 Thousand USD | -73748.147% |
| Alpha Cognition Inc. | 2.45 Million USD | -3015.2% |
| HST Global, Inc. | 1526.00 USD | -5005797.772% |
| CSL Limited | 38.02 Billion USD | 99.799% |
| Halberd Corporation | 10.13 Thousand USD | -753922.308% |
| Enzolytics Inc. | 361.7 Million USD | 78.881% |
| Resverlogix Corp. | 8.11 Million USD | -841.343% |
| Affymax, Inc. | 7.44 Million USD | -926.333% |
| SYBLEU INC | 330.46 Thousand USD | -23015.703% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -3967.885% |
| argenx SE | 4.54 Billion USD | 98.318% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -173.368% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -60.14% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -335223.296% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -753.6% |
| AVAX Technologies, Inc. | 7.37 Million USD | -935.494% |
| Zenith Capital Corp. | 7410.00 USD | -1030804.184% |
| Genscript Biotech Corporation | 3.38 Billion USD | 97.744% |
| Ember Therapeutics, Inc. | 184.00 USD | -41516204.348% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -23637.904% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -29127.438% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 82.884% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -5172.483% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | -2425.217% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -44.95% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -8132.027% |
| BioStem Technologies, Inc. | 14.56 Million USD | -424.646% |
| ONE Bio Corp. | 70.08 Million USD | -8.995% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -133696.896% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -3306826.407% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -7632.04% |
| Agentix Corp. | 261.39 Thousand USD | -29124.307% |
| LadRx Corporation | 2.3 Million USD | -3209.961% |
| Cell Source, Inc. | 195.17 Thousand USD | -39040.036% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -15796.137% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -21502.468% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -21502.468% |
| NovAccess Global Inc. | 62.24 Thousand USD | -122618.802% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -11842.357% |
| Itoco Inc. | 1.4 Million USD | -5356.148% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -79758.244% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -71966.038% |
| Kadimastem Ltd | 2.3 Million USD | -3215.423% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -99947.149% |
| CytoDyn Inc. | 11.13 Million USD | -585.973% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -53330.042% |
| Mobile Lads Corp. | 52.00 USD | -146903746.154% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -427137.136% |
| Qrons Inc. | 420.00 USD | -18187995.238% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -19717.314% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -13735.76% |
| Rebus Holdings, Inc. | 5000.00 USD | -1527700.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -18558.011% |
| International Stem Cell Corporation | 5.39 Million USD | -1317.254% |
| Bioxytran, Inc. | 137.63 Thousand USD | -55400.661% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -409.205% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -360.764% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -96596.203% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -8734.513% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -916.23% |
| Neutra Corp. | 2851.00 USD | -2679310.733% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -135.728% |
| PureTech Health plc | 693.97 Million USD | 88.992% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -846.465% |
| IXICO plc | 15.84 Million USD | -382.141% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -822.362% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 26.068% |
| CSL Limited | 38.02 Billion USD | 99.799% |
| Cellectis S.A. | 333.99 Million USD | 77.128% |